- Home
- SRTS vs PLRX Comparison
SRTS vs PLRX Comparison
Compare SRTS & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRTS | PLRX |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.9M | 79.9M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SRTS | PLRX |
|---|---|---|
| Price | $4.10 | $1.34 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $6.67 | $3.00 |
| AVG Volume (30 Days) | 107.0K | ★ 588.7K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,482,000.00 | N/A |
| Revenue This Year | $3.81 | N/A |
| Revenue Next Year | $38.85 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.03 | $1.09 |
| 52 Week High | $5.92 | $1.95 |
Technical Indicators
Market Signals| Indicator | SRTS | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 60.29 |
| Support Level | $3.63 | $1.12 |
| Resistance Level | $4.86 | $1.36 |
| Average True Range (ATR) | 0.27 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 30.43 | 64.86 |
Price Performance
Historical ComparisonAbout SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.